Compare LIDR & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIDR | IMA |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | 56 | 17 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 66.3M |
| IPO Year | N/A | N/A |
| Metric | LIDR | IMA |
|---|---|---|
| Price | $1.13 | $5.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $4.75 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 664.2K | 8.4K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,604.29 | N/A |
| Revenue Next Year | $466.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $3.94 |
| 52 Week High | $6.44 | $17.50 |
| Indicator | LIDR | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 43.53 |
| Support Level | N/A | $5.36 |
| Resistance Level | $1.77 | $6.13 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 3.19 | 22.45 |
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.